文献速递肝胆胰外科

机器学习预测模型指导术后复发性肝细胞癌的治疗分配

Machine Learning Predictive Model to Guide Treatment Allocation for Recurrent Hepatocellular Carcinoma After Surgery.
PubMed 文献 · JAMA Surg · 2023-01-01

该研究基于意大利2008—2019年注册数据,纳入701例术后复发性肝细胞癌患者,构建机器学习模型预测复发后生存并分配最佳治疗。模型5年AUC为78.5%(95%CI 71.7%-85.3%),按模型87.2%患者可能从再切除或热消融获益,5.2%从索拉非尼获益,7.6%从化疗栓塞获益。

要点

  • 模型可个体化预测复发后生存,指导再切除/热消融、索拉非尼或化疗栓塞的选择。
  • 治疗、年龄、肝硬化、复发结节数目/大小/肝叶位置、肝外转移及复发时间均为疗效修饰因子和生存预测因子。
  • 模型5年AUC为78.5%(95%CI 71.7%-85.3%),外部验证来自意大利和日本队列。

核心结论

  • 基于机器学习算法可按患者特征以治疗分层方式将复发性肝细胞癌患者分配至最佳潜在治疗。

研究设计与样本

  • 研究为基于意大利肝细胞癌注册数据的真实世界研究,纳入2008年1月至2019年12月术后复发肝细胞癌患者,中位随访27(IQR 12-51)个月,并在意大利另一队列和日本队列进行外部验证。
  • 共纳入701例复发性肝细胞癌患者,平均(SD)年龄71(9)岁,女性151例(21.5%)。

主要发现

  • 293例(41.8%)接受再切除或热消融,188例(26.8%)接受索拉非尼,220例(31.4%)接受化疗栓塞。
  • 预测模型在复发后5年的AUC为78.5%(95%CI 71.7%-85.3%)。
  • 按模型,611例(87.2%)可能从再切除或热消融获益,37例(5.2%)从索拉非尼获益,53例(7.6%)从化疗栓塞获益。
  • 索拉非尼、化疗栓塞和再切除或热消融作为最佳潜在治疗的患者中位(IQR)年龄分别为78.5(75.2-83.4)岁、77.02(73.89-80.46)岁和71.59(64.76-76.06)岁。
  • 索拉非尼、化疗栓塞和再切除或热消融作为最佳潜在治疗的患者中位(IQR)多发复发结节数分别为1.00(1.00-2.00)、1.00(1.00-2.00)和2.00(1.00-3.00)。

关键数值与推荐

  • 治疗、年龄、肝硬化、复发结节数目、大小和肝叶位置、肝外转移及复发时间均为疗效修饰因子和复发后生存预测因子。

临床怎么用

  • 该算法可帮助根据复发性肝细胞癌患者的具体特征,以治疗分层方式将其分配至最佳潜在治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clear indications on how to select retreatments for recurrent hepatocellular carcinoma (HCC) are still lacking. OBJECTIVE: To create a machine learning predictive model of survival after HCC recurrence to allocate patients to their best potential treatment. DESIGN, SETTING, AND PARTICIPANTS: Real-life data were obtained from an Italian registry of hepatocellular carcinoma between January 2008 and December 2019 after a median (IQR) follow-up of 27 (12-51) months. External validation was made on data derived by another Italian cohort and a Japanese cohort. Patients who experienced a recurrent HCC after a first surgical approach were included. Patients were profiled, and factors predicting survival after recurrence under different treatments that acted also as treatment effect modifiers were assessed. The model was then fitted individually to identify the best potential treatment. Analysis took place between January and April 2021. EXPOSURES: Patients were enrolled if treated by reoperative hepatectomy or thermoablation, chemoembolization, or sorafenib. MAIN OUTCOMES AND MEASURES: Survival after recurrence was the end point. RESULTS: A total of 701 patients with recurrent HCC were enrolled (mean [SD] age, 71 [9] years; 151 [21.5%] female). Of those, 293 patients (41.8%) received reoperative hepatectomy or thermoablation, 188 (26.8%) received sorafenib, and 220 (31.4%) received chemoembolization. Treatment, age, cirrhosis, number, size, and lobar localization of the recurrent nodules, extrahepatic spread, and time to recurrence were all treatment effect modifiers and survival after recurrence predictors. The area under the receiver operating characteristic curve of the predictive model was 78.5% (95% CI, 71.7%-85.3%) at 5 years after recurrence. According to the model, 611 patients (87.2%) would have benefited from reoperative hepatectomy or thermoablation, 37 (5.2%) from sorafenib, and 53 (7.6%) from chemoembolization in terms of potential survival after recurrence. Compared with patients for which the best potential treatment was reoperative hepatectomy or thermoablation, sorafenib and chemoembolization would be the best potential treatment for older patients (median [IQR] age, 78.5 [75.2-83.4] years, 77.02 [73.89-80.46] years, and 71.59 [64.76-76.06] years for sorafenib, chemoembolization, and reoperative hepatectomy or thermoablation, respectively), with a lower median (IQR) number of multiple recurrent nodules (1.00 [1.00-2.00] for sorafenib, 1.00 [1.00-2.00] for chemoembolization, and 2.00 [1.00-3.00] for reoperative hepatectomy or thermoablation). Extrahepatic recurrence was observed in 43.2% (n = 16) for sorafenib as the best potential treatment vs 14.6% (n = 89) for reoperative hepatectomy or thermoablation as the best potential treatment and 0% for chemoembolization as the best potential treatment. Those profiles were used to constitute a patient-tailored algorithm for the best potential treatment allocation. CONCLUSIONS AND RELEVANCE: The herein presented algorithm should help in allocating patients with recurrent HCC to the best potential treatment according to their specific characteristics in a treatment hierarchy fashion.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Famularo S, Donadon M, Cipriani F, et al. Machine Learning Predictive Model to Guide Treatment Allocation for Recurrent Hepatocellular Carcinoma After Surgery. JAMA Surg. 2023. PMID: 36576813. doi:10.1001/jamasurg.2022.6697

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。